Three 18F-labeled radiopharmaceuticals have been Food and Drug Administration-approved for the identification of cortical amyloidosis in clinical settings. Although there has been strong debate among professionals as to the ethical and social consequences of disclosing such information, increasing numbers of participants are being recruited into secondary prevention trials for which they are likely to, and/or desire to, receive their positron emission tomography (PET) imaging results.
from Dementia Big http://ift.tt/1Pymcum
via Stopping Dementia
from WordPress http://ift.tt/22zBWUX
via alcoholic dementia
http://ift.tt/22zD4b6
No comments:
Post a Comment